Diana Brixner

1.5k total citations · 1 hit paper
37 papers, 977 citations indexed

About

Diana Brixner is a scholar working on Economics and Econometrics, General Health Professions and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Diana Brixner has authored 37 papers receiving a total of 977 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Economics and Econometrics, 6 papers in General Health Professions and 5 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Diana Brixner's work include Health Systems, Economic Evaluations, Quality of Life (16 papers), Pharmaceutical Economics and Policy (8 papers) and Pharmaceutical Practices and Patient Outcomes (5 papers). Diana Brixner is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (16 papers), Pharmaceutical Economics and Policy (8 papers) and Pharmaceutical Practices and Patient Outcomes (5 papers). Diana Brixner collaborates with scholars based in United States, United Kingdom and Netherlands. Diana Brixner's co-authors include Wim Goettsch, Marc L. Berger, John B. Watkins, Amr Makady, Sebastian Schneeweiß, David Madigan, Shirley Wang, Rosanna Tarricone, C. Daniel Mullins and Harold C. Sox and has published in prestigious journals such as American Journal of Hypertension, Value in Health and Health Policy.

In The Last Decade

Diana Brixner

33 papers receiving 941 citations

Hit Papers

Good Practices for Real‐World Data Studies of Treatment a... 2017 2026 2020 2023 2017 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Good Practices for Real‐World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR‐ISPE Special Task Force on Real‐World Evidence in Health Care Decision Making
    2017 327 citations Marc L. Berger, Harold C. Sox et al. Value in Health profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Diana Brixner United States 10 461 194 143 96 79 37 977
Amr Makady Netherlands 12 643 1.4× 171 0.9× 232 1.6× 92 1.0× 77 1.0× 27 1.2k
Eleanor M. Perfetto United States 17 399 0.9× 278 1.4× 89 0.6× 51 0.5× 73 0.9× 81 1.3k
M. Sanni Ali United Kingdom 19 207 0.4× 138 0.7× 176 1.2× 148 1.5× 188 2.4× 45 1.2k
Gregory W. Daniel United States 20 343 0.7× 90 0.5× 138 1.0× 137 1.4× 161 2.0× 46 1.5k
Mark Nuijten Netherlands 12 487 1.1× 199 1.0× 36 0.3× 61 0.6× 94 1.2× 44 954
Jessica A. Myers United States 12 232 0.5× 74 0.4× 210 1.5× 48 0.5× 130 1.6× 21 1.0k
Gerry Gray United States 6 341 0.7× 95 0.5× 239 1.7× 169 1.8× 142 1.8× 9 1.4k
Spencer Phillips Hey United States 21 479 1.0× 213 1.1× 282 2.0× 228 2.4× 94 1.2× 68 1.5k
Petra Schnell‐Inderst Austria 17 279 0.6× 415 2.1× 52 0.4× 104 1.1× 128 1.6× 62 1.5k
Andrew Toren Canada 6 277 0.6× 103 0.5× 68 0.5× 43 0.4× 72 0.9× 10 840

Countries citing papers authored by Diana Brixner

Since Specialization
Citations

This map shows the geographic impact of Diana Brixner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Diana Brixner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Diana Brixner more than expected).

Fields of papers citing papers by Diana Brixner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Diana Brixner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Diana Brixner. The network helps show where Diana Brixner may publish in the future.

Co-authorship network of co-authors of Diana Brixner

This figure shows the co-authorship network connecting the top 25 collaborators of Diana Brixner. A scholar is included among the top collaborators of Diana Brixner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Diana Brixner. Diana Brixner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Brixner, Diana, et al.. (2025). Health Disparities in HIV Care and Strategies for Improving Equitable Access to Care. The American Journal of Managed Care. 31(Suppl 1). S3–S12. 1 indexed citations
3.
Malone, Daniel C., et al.. (2024). An evaluation of vilobelimab (anti-C5a) as a cost-effective option to treat severely ill mechanically ventilated patients with COVID-19. American Journal of Health-System Pharmacy. 82(9). e438–e446.
4.
Ye, Xiangyang, Jim A. Youssef, Ben Goss, et al.. (2024). The relationship of PROMIS physical function scores and healthcare resource utilization in patients treated for chronic low back pain. Interventional Pain Medicine. 3(4). 100522–100522.
5.
Schabath, Matthew B., Jonathan P. Thompson, Jyoti Malhotra, et al.. (2024). Clinical characteristics and treatment patterns of patients with NTRK fusion–positive solid tumors: A multisite cohort study at US academic cancer centers. Journal of Managed Care & Specialty Pharmacy. 30(7). 672–683. 1 indexed citations
6.
Thompson, J. L., Jyoti Malhotra, Gilbert Ko, et al.. (2022). CO118 TRK Inhibitor Treatment Patterns in Patients with NTRK Fusion-Positive Solid Tumors: A Multi-Site Cohort Study at U.S. Academic Cancer Centers. Value in Health. 25(12). S41–S41. 1 indexed citations
7.
8.
Sarri, Grammati, Andreas Freitag, Irina Mountian, et al.. (2021). The Role of Patient Experience in the Value Assessment of Complex Technologies – Do HTA Bodies Need to Reconsider How Value is Assessed?. Health Policy. 125(5). 593–601. 6 indexed citations
9.
Giannouchos, Theodoros V., Joseph Biskupiak, Michael J. Moss, et al.. (2020). Trends in outpatient emergency department visits during the COVID-19 pandemic at a large, urban, academic hospital system. The American Journal of Emergency Medicine. 40. 20–26. 65 indexed citations
10.
Berger, Marc L., Harold C. Sox, Richard J. Willke, et al.. (2017). Good Practices for Real‐World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR‐ISPE Special Task Force on Real‐World Evidence in Health Care Decision Making. Value in Health. 20(8). 1003–1008. 327 indexed citations breakdown →
11.
Ye, Xiangyang, Sudhir Unni, Christopher F. Dowd, et al.. (2016). Development Of A Linked Database For Cystic Fibrosis Research By Integrating A Patient Registry With Administrative Claims Data. Value in Health. 19(3). A81–A81. 1 indexed citations
12.
Bress, Adam P., et al.. (2015). Value Assessment for Genetic Testing of Drug Variation In An Elderly Population. Value in Health. 18(7). A747–A747. 2 indexed citations
13.
Saverno, Kim, et al.. (2014). Consideration of international generic distribution policies on patient outcomes in the United States and Germany.. PubMed. 69(3). 238–40. 3 indexed citations
14.
15.
Saverno, Kim, et al.. (2013). The Impact of Generic Substitution on Health Outcomes and Costs: A Systematic Review. Value in Health. 16(7). A458–A458. 1 indexed citations
16.
Holtorf, Anke‐Peggy, et al.. (2012). Current and Future Use of HEOR Data in Healthcare Decision-Making in the United States and in Emerging Markets.. PubMed. 5(7). 428–38. 12 indexed citations
17.
Smith, Marilyn Dix, Michael Drummond, & Diana Brixner. (2009). Moving the QALY Forward: Rationale for Change. Value in Health. 12. S1–S4. 39 indexed citations
18.
Drummond, Michael, Diana Brixner, Marthe R. Gold, et al.. (2009). Toward a Consensus on the QALY. Value in Health. 12. S31–S35. 92 indexed citations
19.
Gunter, Marc J., et al.. (2004). Impact of a Seizure Disorder Disease Management Program on Patient-Reported Quality of Life. Disease Management. 7(4). 333–347. 15 indexed citations
20.
Gunning, Karen, et al.. (2003). PHP21: REVIEWS OF UTAH MEDICAID HIGH UTILIZERS TO CONTROL DRUG COSTS. Value in Health. 6(3). 206–206. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Amr Makady Breakdown of academic impact, for papers by Eleanor M. Perfetto Breakdown of academic impact, for papers by M. Sanni Ali Breakdown of academic impact, for papers by Gregory W. Daniel Breakdown of academic impact, for papers by Mark Nuijten Breakdown of academic impact, for papers by Jessica A. Myers Breakdown of academic impact, for papers by Gerry Gray Breakdown of academic impact, for papers by Spencer Phillips Hey Breakdown of academic impact, for papers by Petra Schnell‐Inderst Breakdown of academic impact, for papers by Andrew Toren
Rankless by CCL
2026